VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
Sep 1, 2017Toronto, Ontario: Apotex Inc. announced today that it is conducting a voluntary nationwide recall of one lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex Standard, 0.4MG/METERED DOSE, UPC number 771313217279 and DIN number 02393433 to the Wholesalers, Distributors, Retailers, and Patients level. The impacted lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex Standard, 0.4MG/METERED DOSE may contain a non-spraying pump.
A non-spraying pump will result in lack of administration of nitroglycerin to the patient. The potential outcome is inadequate management of angina control which could result in a heart attack.
The product is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. For further details, please refer to the package insert. The product is packaged as 200 metered doses in a bottle. The affected APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex Standard, 0.4MG/METERED DOSE lot is as follows:
| Lot Number | Expiry Date |
|---|---|
| 6G07 | 01/2019 |
The product can also be identified by UPC 771313217279 and DIN 02393433. The impacted lot was distributed nationwide in the Canada to wholesalers and distributors by Apotex between March 31, 2017 and June 23, 2017.
Apotex will notify impacted direct account customers by sending the recall notification letter by UPS Express (international) service and is arranging for return of the impacted product lot.
Patients who have received the impacted lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray, 0.4mg / metered dose) should return the product to a pharmacy for replacement. Additionally, patients/consumers may contact Apotex Inc. via Stericycle by calling at 1-855-215-5004 or by email [email protected] if they have any question about the recall.
To report a suspected adverse reaction associated with the use of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray,0.4mg / metered dose) patients may contact Apotex by calling 1-800-667-4708 (select prompt 2), by email at [email protected] or by fax at 1-866-429-9133 or 416-401-3819.
Patients may also report any suspected adverse reactions associated with the use of health products to Health Canada by calling toll free at 1-866-234-2345 or by visiting MedEffect Canada's Web page on Adverse Reaction Reporting https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html for information on how to report online, by mail or by fax.
Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with more than 8,000 employees worldwide. With its worldwide manufacturing sites, Apotex can produce up to 25 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex will spend $2 billion over the next 10 years on research and development.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.